A Prospective, Phase I, Double-blind, Parallel-group, Placebo-controlled, Randomised Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ACD856 in Healthy Volunteers

The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers.
ACD856 will be administered orally.

开始日期2021-09-29

申办/合作机构

AlzeCure Pharma AB

NCT05077631 / Completed临床1期

A Phase I, Double-Blind, Placebo-controlled, Randomized Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics in Healthy Adults

The SAD design of the study is based on the aim to study safety, tolerability and PK of selected doses of ACD856 in a limited number of healthy volunteers. ACD856 will be administered orally.

开始日期2021-02-15

申办/合作机构

AlzeCure Pharma AB

NCT05783830 / Completed早期临床1期

A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers

This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy subjects.

开始日期2020-01-13

申办/合作机构

AlzeCure Pharma AB

100 项与 ACD-856 相关的临床结果

登录后查看更多信息

100 项与 ACD-856 相关的转化医学

登录后查看更多信息

100 项与 ACD-856 相关的专利（医药）

登录后查看更多信息

项与 ACD-856 相关的文献（医药）

2024-05-01·European journal of clinical pharmacology

ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics

Article

作者: Bylund, Johan ; Segerdahl, Märta ; Rother, Matthias ; Nilsson, Boel ; Rein-Hedin, Erik ; Halldin, Magnus M ; Önnestam, Kristin

Abstract:

Purpose:

AlzeCure Pharma AB is developing novel positive allosteric modulators of Trk-receptors for treatment of Alzheimer’s disease, depression, other psychiatric conditions and other disorders where cognition is impaired. The preceding candidate drug ACD855 was shown to have a too long half-life in humans to allow further development. To de-risk the development of the follow-up compound ACD856, the oral single ascending dose study of ACD856 in humans was preceded by an intravenous microdose study, assessing the elimination half-life in plasma.

Methods:

A phase 0 study with a microdose of ACD856 (0.100 mg), was conducted in six healthy male subjects all receiving ACD856. Sequentially, a randomized, placebo-controlled, double-blind Phase I single ascending oral dose study (1 – 150 mg) was conducted, including 56 healthy subjects. Both studies assessed the safety and tolerability, as well as the PK properties of ACD856 after single dose intravenous and oral administration.

Results:

ACD856 was well tolerated with no treatment emergent, or dose related adverse events or other safety assessments. In the microdose study, ACD856 exhibited a bi-exponential plasma decline, low distribution volume, low plasma clearance with a half-life of approximately 20 hours. Orally, ACD856 exhibited rapid absorption, an almost complete bioavailability and a dose proportional increase in exposure. While the Cmax was lowered and delayed by food intake, the effect on plasma half-life and the overall bioavailability was low. No renal elimination of ACD856 was detected.

Conclusion:

The prediction proved accurate demonstrating the value of conducting a microdose study prior to ascending dose studies.

Trial registration:

NCT05783830 March 24, 2023 (microdose study, retrospectively registered) and NCT05077631 October 14, 2021 (single ascending dose study).

2023-08-01·Psychopharmacology

Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?

Article

作者: Nordvall, Gunnar ; Forsell, Pontus ; Ögren, Sven-Ove ; Sandin, Johan ; Lidell, Veronica ; Lindskog, Maria ; Madjid, Nather

BACKGROUND:

Major depressive disorder (MDD) is defined as a complex mental disorder which is characterized by a pervasive low mood and aversion to activity. Several types of neurotransmitter systems e.g. serotonergic, glutamatergic and noradrenergic systems have been suggested to play an important role in the origination of depression, but neurotrophins such as brain derived neurotrophic factor (BDNF) have also been implicated in the disease process.

OBJECTIVES:

The purpose of this study was to examine the effects of a newly developed class of molecules, characterized as positive allosteric modulators of neurotrophin/Trk receptor mediated signaling (Trk-PAM), on neurotransmitter release and depression-like behavior in vivo.

METHODS:

The effect of and possible interaction of neurotrophin/Trk signaling pathways with serotonergic and glutamatergic systems in the modulation of depression-related responses was studied using newly developed Trk-PAM compounds (ACD855, ACD856 and AC26845), as well as ketamine and fluoxetine in the forced swim test (FST) in rodents. Moreover, in vivo microdialysis in freely moving rats was used to assess changes in neurotransmitter levels in the rat.

RESULTS:

The results from the study show that several different compounds, which all potentiate Trk-receptor mediated signaling, display antidepressant-like activity in the FST. Moreover, the data also indicate that the effects of both fluoxetine and ketamine in the FST, both used in clinical practice, are mediated via BDNF/TrkB signaling, which could have implications for novel therapies in MDD.

CONCLUSIONS:

Trk-PAMs could provide an interesting avenue for the development of novel therapeutics in this area.

2023-01-01·The journal of prevention of Alzheimer's disease

Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.

Article

作者: Rein-Hedin, E ; Sandin, J ; Halldin, M M ; Anderer, P ; Nilsson, B ; Kemethofer, M ; Segerdahl, M ; Önnestam, K ; Rother, M ; Bylund, J

BACKGROUND:

ACD856 is a positive allosteric modulator of tropomyosin receptor kinase (Trk) receptors which has shown to have pro-cognitive and anti-depressant-like effects in various animal models. It is currently in clinical development for the treatment of Alzheimer's disease and other disorders where cognition is impaired and is also considered for indications such as depression or other neuropsychiatric diseases. ACD856 has a novel mechanism of action modulating the activity of the Trk-receptors, resulting in increased stimulation of the neurotrophin signaling pathways. Previous studies applying single intravenous and oral doses of ACD856 indicate that ACD856 is safe and well-tolerated by healthy volunteer subjects, and that it has suitable safety and pharmacokinetic properties for further clinical development.

OBJECTIVES:

To investigate the safety and tolerability of 7 days of treatment with multiple ascending oral doses of ACD856 in healthy subjects, and to characterize its pharmacokinetic (PK) properties. In addition, pharmacodynamic effects of ACD856 using quantitative electroencephalography (qEEG) as an indicator for central target engagement were assessed.

DESIGN:

This was a prospective, phase I, double-blind, parallel-group, placebo-controlled, randomized study of the safety, tolerability, PK and pharmacodynamics of multiple ascending oral doses of ACD856 in healthy subjects. ACD856 or placebo were administered in 3 ascending dose cohorts of 8 subjects. Within each cohort, subjects were randomized to receive either ACD856 (n=6) or placebo (n=2).

SETTING:

The study was conducted at a First-in-Human unit in Sweden.

PARTICIPANTS:

Twenty-four healthy male and female subjects.

INTERVENTION:

The study medication was administered as an oral solution, with ACD856 or the same contents without the active ingredient (placebo). The dose levels ranged from 10 mg to 90 mg. ACD856 was administered once daily for 7 days, targeting steady state.

MEASUREMENTS:

Safety and tolerability assessments included adverse events, laboratory, vital signs, 12-lead electrocardiogram (ECG), physical examination, assessment of stool frequency and questionnaires to assess symptoms of anxiety, depression, as well as suicidal ideation and behavior. In addition, cardiodynamic ECGs were extracted to evaluate cardiac safety. PK parameters were calculated based on measured concentrations of ACD856 in plasma, urine, and cerebrospinal fluid (CSF) samples. Metabolite profiling, characterization and analysis was performed based on and urine samples. qEEG was recorded for patients in the two highest dose cohorts (30 and 90 mg/day) as a pharmacodynamic assessment to explore central target engagement.

RESULTS:

Treatment with ACD856 was well tolerated with no serious adverse events. No treatment emergent or dose related trends were observed for any of the safety assessments. ACD856 was rapidly absorbed and reached maximum plasma exposure at 30 to 45 minutes after administration. Steady state was reached before Day 6, with an elimination half-life at steady state of approximately 20 hours. At steady state, ACD856 exhibited accumulation ratios for Cmax and AUC of approximately 1.6 and 1.9 respectively. The exposure, Cmax and AUC0-24, increased proportionally with the dose. There was no unchanged ACD856 detected in urine. The metabolic pattern in urine and plasma was similar, and in alignment with the metabolites observed in preclinical toxicology studies. The level of ACD856 measured in CSF at steady state increased with dose, indicating Central Nervous System (CNS) exposure at relevant levels for pharmacodynamic effects. ACD856 demonstrated significant dose-dependent treatment-associated changes on qEEG parameters. Specifically, increase of the relative theta power and decrease of the fast alpha and beta power was observed, leading to an acceleration of the delta+theta centroid and an increase in the theta/beta ratio.

CONCLUSIONS:

ACD856 was well tolerated at the tested dose levels (10-90 mg/daily for 7 days) in healthy subjects. The compound has a robust pharmacokinetic profile, with rapid absorption and dose-dependent exposure. ACD856 was shown to pass the blood-brain-barrier, reach relevant exposure in the CNS and to induce dose-dependent treatment-related changes on qEEG parameters, indicating central target engagement.

项与 ACD-856 相关的新闻（医药）

2024-05-13

·BioSpace

AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the company has received preclinical data for NeuroRestore in inflammation, with relevance to Alzheimer's disease, and submitted a new patent application for NeuroRestore ACD856, which is now being prepared for phase II clinical studies. "Alzheimer's disease as well as other neurodegenerative diseases are characterized by an inflammatory process in the brain. Prolonged inflammation, with the release of inflammatory and toxic substances, can cause damage and nerve cell death. That we can target these inflammatory processes is something that further opens up new possibilities for ACD856," said Pontus Forsell, Head of Discovery and Research at AlzeCure. New preclinical data show that the NeuroRestore substance ACD856 exhibits anti-inflammatory properties both centrally in the brain and peripherally in the body with relief of clinical inflammatory symptoms in preclinical models and a reduction in several inflammatory markers. These new data indicate an opportunity to treat diseases with elements of neuroinflammation, such as Alzheimer's disease, and that ACD856 can have a disease-modifying effect via its anti-inflammatory properties. ACD856 and the other substances in the NeuroRestore platform stimulate several important signaling systems and signaling substances in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances. The biological mechanism behind NeuroRestore enables several indications, such as Alzheimer's and Parkinson's disease, but also depression. "We continue to strengthen the patent portfolio for our NeuroRestore program, and already have approved patents in all major markets such as the USA, Europe, Japan and China. The new results for our clinical drug candidate ACD856, which we are preparing for phase II against Alzheimer's, provide further evidence for a disease-modifying effect as well as general use against neurodegenerative diseases, where neuroinflammation is central. This further improves our commercial opportunities for this promising substance," said Martin Jönsson, CEO. For more information, please contact Martin Jönsson, CEO Tel: +46 707 86 94 43 martin.jonsson@alzecurepharma.com About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . About NeuroRestore NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. Preclinical studies with NeuroRestore have shown that AlzeCure's drug candidates enhance communication between the nerve cells and improve cognitive ability. The NeuroRestore substances are so called Trk-PAMs which stimulate specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years. In addition to cognitive-enhancing effects, new preclinical data also show that NeuroRestore substances have a positive effect on mitochondrial function and cell survival, which could indicate potential disease-modifying effects. The leading drug candidate in the platform, ACD856, has recently completed clinical phase I studies and demonstrated positive effects there that support continued development of the program. About Alzheimer's disease Alzheimer's disease is the most common form of dementia, affecting approximately 55 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases are estimated to about 1,300 billion USD globally in 2019. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined. Image Attachments Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma Attachments AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application SOURCE: AlzeCure Pharma View the original press release on accesswire.com

临床1期临床2期

2024-04-25

·BioSpace

AlzeCure Publishes its Interim Report for January - March 2024

STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March 2024 is now available on the company's website: "The first quarter of 2024 was positive and active for AlzeCure Pharma. In our clinical Alzheimer's program, NeuroRestore ACD856, we presented new preclinical data supporting neuroprotective and disease-modifying effects at the major international Alzheimer's conference AD/PD 2024. In addition, we had patents for NeuroRestore and ACD856 approved in China and several other countries, which strengthens our business development opportunities. During the quarter, we also selected a drug candidate in our pain project for treatment of knee osteoarthritis, TrkA-NAM. Our research and development was also further recognized by a government and ministerial visit, as well as by an investment by Eli Lilly's former global head of research and development, Dr. Jan Lundberg, who was also global head of research for AstraZeneca. He has also made himself available for a position on the company's Board of Directors, which is supported by the nomination committee. To finance the further development of the above-mentioned drug candidates, and to strengthen the company's financial position, the Board of Directors proposed during the quarter a rights issue of approximately SEK 52.8 million. It is both motivating and gratifying that the company is keeping up the pace as it continues to deliver new data that strengthen our position, and that we are receiving increasing recognition from external parties." Martin Jönsson, CEO Financial information for January - March, 2024 Figures in parentheses refer to the corresponding period of the previous year. Net sales during the period totaled SEK 0 thousand (0). Loss for the period totaled SEK -9,804 thousand (-9,545). Earnings per share, basic, totaled SEK -0.16 (-0.15). Cash flow from operating activities totaled SEK -10,063 thousand (28,095). Total assets at the end of the period amounted to SEK 22,688 thousand (57,974). Cash and cash equivalents at the end of the period totaled SEK 19,037 thousand (53,718). Significant events during the period January - March, 2024 On January 29, the company selects a drug candidate and enters the next phase of development with TrkA-NAM ACD137 for the treatment of osteoarthritis and other severe pain conditions. On February 29, the company announces that the patent offices in China, India, South Africa, Israel, Hong Kong and Mexico have granted patents covering the company's clinical drug candidate ACD856, which is being developed for Alzheimer's and other cognitive disorders. On March 26, the company's Board of Directors resolved on a new issue of shares of approximately SEK 52.8 million with preferential rights for existing shareholders. The Rights Issue is subject to approval by the Extraordinary General Meeting on April 25, 2024. The issue is guaranteed to approximately 63 percent through subscription commitments and guarantee commitments from existing owners and members of the company's management and Board of Directors, among others. To enable further capital injections, the Board of Directors may also exercise an overallotment option of up to approximately SEK 15.0 million. On March 26, the company announces that an Extraordinary General Meeting will convene on April 25, 2024. Significant events after the end of the period On April 10, the company announces that its Annual General Meeting will convene on May 14, 2024. On April 10, the company announces that Dr. Jan Lundberg, former head of research at Eli Lilly and AstraZeneca, is investing in AlzeCure and proposes that he be elected to serve on the company's Board of Directors. The full report is attached as PDF and is available on the company's website: For more information, please contact Martin Jönsson, CEO Tel: +46 707 86 94 43 martin.jonsson@alzecurepharma.com About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Attachments Alzecure Q1 2024 ENG SOURCE: AlzeCure Pharma View the original press release on accesswire.com

上市批准财报

2024-04-04

·BioSpace

AlzeCure Pharma Publishes its Annual Report for 2023

STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that its Annual Report for 2023 has been published. "2023 continued to be positive and eventful for AlzeCure Pharma. During the year, we presented positive proof-ofmechanism (POM) results from our Phase II clinical study with ACD440 for the treatment of neuropathic pain. Further, we chose a new candidate drug for our Alzheimer's project, Alzstatin, and we also published new preclinical data for our clinical drug candidate NeuroRestore ACD856, which supports neuroprotective and disease-modifying effects. This advancement is highly relevant for treatment of Alzheimer's and other neurodegenerative diseases. We were also granted patents for ACD856 in additional territories, such as in Europe and Japan, further strengthening our business development opportunities. Furthermore, we have now also selected a drug candidate in our TrkA-NAM project, ACD137. It is both motivating and gratifying that we are keeping up the pace as we continue to deliver new data that strengthen our position," says Martin Jönsson, CEO of AlzeCure Pharma. The Annual Report is attached as a PDF and is available on the company's website, For more information, please contact Martin Jönsson, CEO Tel: +46 707 86 94 43 martin.jonsson@alzecurepharma.com About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease, as well as for depression treatment. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions, alternatively partnership, with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit . Attachments Alzecure AR 2023 ENG Final SOURCE: AlzeCure Pharma View the original press release on accesswire.com

临床结果临床2期

100 项与 ACD-856 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床1期	瑞典	AlzeCure Pharma AB	2021-02-15
认知障碍	临床1期	瑞典	AlzeCure Pharma AB	2021-02-15
抑郁症	临床1期	-	AlzeCure Pharma AB	-
帕金森病	临床1期	-	AlzeCure Pharma AB	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05783830 \| NCT05077631 (ACD856, Pubmed)	N/A	-	-	ACD856 1 mg	憲憲獵獵餘鏇鏇網窪淵(製壓廠餘夢獵鏇艱鹹窪) = 獵餘餘顧糧構網廠窪糧襯壓衊選觸鬱範繭遞觸 (觸遞築願齋蓋鏇衊觸鹽 )	积极	2024-02-14
				ACD856 150 mg	憲憲獵獵餘鏇鏇網窪淵(製壓廠餘夢獵鏇艱鹹窪) = 夢鹽憲顧艱壓醖願製鬱襯壓衊選觸鬱範繭遞觸 (觸遞築願齋蓋鏇衊觸鹽 )
NCT05077501 (Literature) 人工标引	临床1期	-	24	ACD 856	觸齋鹹築積鑰艱築夢願(艱獵廠窪觸獵簾壓觸廠) = 構積繭醖醖膚積願醖積膚鑰齋糧鑰築廠廠艱鑰 (選積鹹築鑰製繭衊醖遞 )	积极	2022-08-02
				Placebo	-